1832 Asset Management’s Pacira BioSciences PCRX Stock Holding History

1832 Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-625,600	Closed	-$59.9M	–	651
2014 Q3	$59.9M	Buy	625,600 +97,700	+19%	+$9.5M	0.2%	125
2014 Q2	$48.2M	Buy	+527,900	New	+$40.2M	0.15%	152

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1832 Asset Management's PCRX Position: Q4 2014 in Review

1832 Asset Management sold out of Pacira BioSciences (PCRX) in Q4 2014, closing a stake of 625,600 shares — an estimated $59.9M sold.

1832 Asset Management first reported a position in PCRX in Q2 2014 and held it in 2 quarters. The position peaked at $59.9M in Q3 2014. 200 funds tracked by Wall St. Rank hold PCRX as of Q4 2014.

1832 Asset Management reported no remaining Pacira BioSciences position as of Q4 2014 after selling out during the quarter.
1832 Asset Management sold 625,600 Pacira BioSciences shares in Q4 2014, an estimated $59.9M.
1832 Asset Management first reported a position in Pacira BioSciences in Q2 2014 and held it in 2 quarters.
1832 Asset Management's Pacira BioSciences position peaked at $59.9M in Q3 2014.
200 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2014.

Based on 1832 Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.